At a glance
| Common trade name | SNAP-8 |
|---|---|
| Molecular size | Eight amino acids |
| Different molecule | Acetyl hexapeptide-3/8 |
| Published human context | Multi-active hyaluronic-acid microneedle patches |
| Evidence limitation | Peptide contribution not isolated |
Overview
The eight-residue ingredient acetyl octapeptide-3 should not be confused with acetyl hexapeptide-3, an older name for acetyl hexapeptide-8. That naming distinction changes which studies are relevant. SNAP-8 is a commercial ingredient context, not a synonym for botulinum toxin or proof of a clinically equivalent effect. Published work includes formulations that combine the peptide with other actives and a delivery device. Such a product may change skin appearance, yet the result cannot identify which component produced the change. The vehicle, hydration, physical microneedling effect, and other ingredients are all plausible contributors requiring controlled comparison.
How it works
The ingredient is marketed around modulation of expression-related signaling, building on the SNAP-25-inspired cosmetic-peptide concept. A proposed neurotransmission mechanism does not demonstrate that a conventional cream reaches the relevant neural structures. Microneedle delivery intentionally changes the skin barrier, so evidence from that delivery system cannot be treated as evidence that simple application to intact skin has the same exposure or effect.
What the patch study can establish
A 12-week single-center study evaluated hyaluronic-acid microneedle patches containing acetyl octapeptide-3, other peptides, adenosine, and seaweed extracts. Instrumental measurements improved and the product was tolerated in that study. Because it tested a combined product and delivery system, the findings do not quantify the independent effect of acetyl octapeptide-3.
Supporting sources [1]
A common citation mismatch
The trial titled as a combination of tripeptide-10 citrulline and acetyl hexapeptide-3 does not study acetyl octapeptide-3. The molecule name differs even though both appear in expression-line marketing. That study therefore cannot establish SNAP-8 efficacy, even when a product description cites it alongside claims about expression lines.
Supporting sources [2]
Cosmetic scope
The manufacturer identifies SNAP-8 as a cosmetic ingredient solution. That identity does not establish an injectable use or unrestricted safety of raw material. Cosmetic status is not FDA drug approval. Product-specific tolerability and appropriate evidence for the delivery method remain necessary.
Reading this profile
Jurisdiction: United States; status and indications may differ elsewhere. Molecular class: Acetylated synthetic octapeptide cosmetic ingredient.
This profile was written with AI-assisted research and checked against the linked sources. It has not been represented as a clinician’s review. Evidence summaries describe the cited studies and products; they do not establish that a separately purchased preparation is equivalent.
Sources & references
Follow the original material. Product labels define specific formulations and uses; trial registration describes a study and does not by itself establish benefit.
- Bioactive-peptide hyaluronic-acid microneedle patches: single-center clinical study ↗Clinical trial source · Checked 2026-10-27
- Different ingredient: acetyl hexapeptide-3 with tripeptide-10 citrulline ↗Clinical trial source · Checked 2026-10-27
- Lubrizol: SNAP-8 peptide solution C product identity ↗Manufacturer / sponsor · Checked 2026-10-27
- FDA: authority over cosmetics and the distinction from drug approval ↗Regulatory source · Checked 2026-10-27